Edgar Filing: MOMENTA PHARMACEUTICALS INC - Form 4

MOMENTA PHARMACEUTICALS INC

Form 4

January 04, 2006

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB Number:

3235-0287

OMB APPROVAL

Expires:

response...

Estimated average

burden hours per

January 31, 2005

0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF subject to Section 16.

Form 4 or Form 5 obligations may continue.

Check this box

if no longer

SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940 See Instruction

1(b).

(Print or Type Responses)

C/O MOMENTA

1. Name and Address of Reporting Person * Venkataraman Ganesh

5. Relationship of Reporting Person(s) to

Symbol

MOMENTA

PHARMACEUTICALS INC

2. Issuer Name and Ticker or Trading

(Check all applicable)

[MNTA]

(Last) (First) (Middle) 3. Date of Earliest Transaction

(Month/Day/Year)

10% Owner Director X_ Officer (give title Other (specify below) Senior V.P., Research

12/30/2005

PHARMACEUTICALS, INC., 675 WEST KENDALL STREET

> (Street) 4. If Amendment, Date Original

> > Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check

Applicable Line)

X Form filed by One Reporting Person Form filed by More than One Reporting

Issuer

CAMBRIDGE, MA 02142

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

Price

1.Title of Security (Instr. 3)

2. Transaction Date 2A. Deemed

(Month/Day/Year) Execution Date, if any

(Month/Day/Year)

3. 4. Securities TransactionAcquired (A) or Code Disposed of (D) (Instr. 8) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following

6. Ownership 7. Nature of Indirect Form: Direct (D) or Indirect Beneficial Ownership (Instr. 4) (Instr. 4)

(A) or Code V Amount (D)

Reported Transaction(s) (Instr. 3 and 4)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of **SEC 1474** information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: MOMENTA PHARMACEUTICALS INC - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount Underlying Securitie (Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amour or Number of Shar
Stock Option (right to buy)	\$ 0.99	12/30/2005		D <u>(1)</u>		31,200	<u>(2)</u>	04/06/2014	Common Stock	7,20
Stock Option (right to buy)	\$ 4.91	12/30/2005		A <u>(1)</u>	31,200		(3)	04/06/2014	Common Stock	31,20

Reporting Owners

Reporting Owner Name / Address

Director 10% Owner Officer Other

Venkataraman Ganesh C/O MOMENTA PHARMACEUTICALS, INC. 675 WEST KENDALL STREET CAMBRIDGE, MA 02142

Senior V.P., Research

Signatures

/s/ Ganesh

Venkataraman 01/04/2006

**Signature of Reporting Date

Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

On December 30, 2005, in an effort to avoid adverse tax consequences to the Reporting Person under 409A of the Internal Revenue Code, the Issuer and the Reporting Person amended an oustanding stock option to purchase 38,400 shares with an exercise price of \$0.99 per share (the "Original Option"). As amended, the portion of the Original Option vested as of December 31, 2004, or 7,200 shares, shall

- remain in full force and effect and continue to have an exercise price of \$0.99. The remaining portion of the Original Option shall be deemed to be cancelled and a replacement option for the purchase of 31,200 shares shall be deemed granted to the Reporting Person with an increased exercise price equal to \$4.91 (the "Replacement Option").
- As of December 31, 2004, the Original Option was vested as to 7,200 shares, and the reporting person may exercise such option as to such number of shares for a per share exercise price of \$0.99.
- As of January 1, 2006, the Replacement Option was vested as to 12,000 shares, and the Reporting Person may exercise such option as to such number of shares for a per share exercise price of \$4.91. The remaining portion of the Replacement Option vests as to 6.25% of the shares at the end of each three-month period following January 1, 2006.

(4) Includes multiple option grants with different prices and vesting dates.

Reporting Owners 2

Edgar Filing: MOMENTA PHARMACEUTICALS INC - Form 4

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.